Unknown

Dataset Information

0

A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics.


ABSTRACT: Combination chemotherapy is crucial for successfully treating cancer. However, the enormous number of possible drug combinations means discovering safe and effective combinations remains a significant challenge. To improve this process, we conduct large-scale targeted CRISPR knockout screens in drug-treated cells, creating a genetic map of druggable genes that sensitize cells to commonly used chemotherapeutics. We prioritize neuroblastoma, the most common extracranial pediatric solid tumor, where ~50% of high-risk patients do not survive. Our screen examines all druggable gene knockouts in 18 cell lines (10 neuroblastoma, 8 others) treated with 8 widely used drugs, resulting in 94,320 unique combination-cell line perturbations, which is comparable to the largest existing drug combination screens. Using dense drug-drug rescreening, we find that the top CRISPR-nominated drug combinations are more synergistic than standard-of-care combinations, suggesting existing combinations could be improved. As proof of principle, we discover that inhibition of PRKDC, a component of the non-homologous end-joining pathway, sensitizes high-risk neuroblastoma cells to the standard-of-care drug doxorubicin in vitro and in vivo using patient-derived xenograft (PDX) models. Our findings provide a valuable resource and demonstrate the feasibility of using targeted CRISPR knockout to discover combinations with common chemotherapeutics, a methodology with application across all cancers.

SUBMITTER: Lee HM 

PROVIDER: S-EPMC10643606 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


Combination chemotherapy is crucial for successfully treating cancer. However, the enormous number of possible drug combinations means discovering safe and effective combinations remains a significant challenge. To improve this process, we conduct large-scale targeted CRISPR knockout screens in drug-treated cells, creating a genetic map of druggable genes that sensitize cells to commonly used chemotherapeutics. We prioritize neuroblastoma, the most common extracranial pediatric solid tumor, wher  ...[more]

Similar Datasets

| S-EPMC10074549 | biostudies-literature
| S-EPMC10180450 | biostudies-literature
| S-EPMC6178919 | biostudies-literature
| S-EPMC7754657 | biostudies-literature
| S-EPMC7183004 | biostudies-literature
| S-EPMC6525321 | biostudies-literature
| S-EPMC8842129 | biostudies-literature
| S-EPMC7523013 | biostudies-literature
| S-EPMC7125811 | biostudies-literature
| S-EPMC10907405 | biostudies-literature